De Pablo Moreno, J. A., Miguel Batuecas, A., Rodríguez Merchán, E. C., & Liras Martín, A. (2023). Treatment of congenital coagulopathies, from biologic to biotechnological drugs: The relevance of gene editing (CRISPR/Cas).
Citación estilo ChicagoDe Pablo Moreno, Juan Andrés, Andrea Miguel Batuecas, E. Carlos Rodríguez Merchán, y Antonio Liras Martín. Treatment of Congenital Coagulopathies, From Biologic to Biotechnological Drugs: The Relevance of Gene Editing (CRISPR/Cas). 2023.
Cita MLADe Pablo Moreno, Juan Andrés, Andrea Miguel Batuecas, E. Carlos Rodríguez Merchán, y Antonio Liras Martín. Treatment of Congenital Coagulopathies, From Biologic to Biotechnological Drugs: The Relevance of Gene Editing (CRISPR/Cas). 2023.
Precaución: Estas citas no son 100% exactas.